232 related articles for article (PubMed ID: 31161832)
1. Devil Facial Tumours: Towards a Vaccine.
Owen RS; Siddle HV
Immunol Invest; 2019 Oct; 48(7):719-736. PubMed ID: 31161832
[TBL] [Abstract][Full Text] [Related]
2. The immunopeptidomes of two transmissible cancers and their host have a common, dominant peptide motif.
Gastaldello A; Ramarathinam SH; Bailey A; Owen R; Turner S; Kontouli N; Elliott T; Skipp P; Purcell AW; Siddle HV
Immunology; 2021 Jun; 163(2):169-184. PubMed ID: 33460454
[TBL] [Abstract][Full Text] [Related]
3. Inducible IFN-γ Expression for MHC-I Upregulation in Devil Facial Tumor Cells.
Ong CEB; Lyons AB; Woods GM; Flies AS
Front Immunol; 2018; 9():3117. PubMed ID: 30692995
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal plasticity of devil facial tumour cells during in vivo vaccine and immunotherapy trials.
Patchett AL; Tovar C; Blackburn NB; Woods GM; Lyons AB
Immunol Cell Biol; 2021 Aug; 99(7):711-723. PubMed ID: 33667023
[TBL] [Abstract][Full Text] [Related]
5. A human adenovirus encoding IFN-γ can transduce Tasmanian devil facial tumour cells and upregulate MHC-I.
Kayigwe AN; M Darby J; Lyons AB; L Patchett A; Lisowski L; Liu GS; S Flies A
J Gen Virol; 2022 Nov; 103(11):. PubMed ID: 36382885
[TBL] [Abstract][Full Text] [Related]
6. Class II transactivator induces expression of MHC-I and MHC-II in transmissible Tasmanian devil facial tumours.
Ong CEB; Cheng Y; Siddle HV; Lyons AB; Woods GM; Flies AS
Open Biol; 2022 Oct; 12(10):220208. PubMed ID: 36259237
[TBL] [Abstract][Full Text] [Related]
7. The newly-arisen Devil facial tumour disease 2 (DFT2) reveals a mechanism for the emergence of a contagious cancer.
Caldwell A; Coleby R; Tovar C; Stammnitz MR; Kwon YM; Owen RS; Tringides M; Murchison EP; Skjødt K; Thomas GJ; Kaufman J; Elliott T; Woods GM; Siddle HV
Elife; 2018 Aug; 7():. PubMed ID: 30103855
[TBL] [Abstract][Full Text] [Related]
8. The role of MHC genes in contagious cancer: the story of Tasmanian devils.
Caldwell A; Siddle HV
Immunogenetics; 2017 Aug; 69(8-9):537-545. PubMed ID: 28695294
[TBL] [Abstract][Full Text] [Related]
9. Curse of the devil: molecular insights into the emergence of transmissible cancers in the Tasmanian devil (Sarcophilus harrisii).
Patchett AL; Flies AS; Lyons AB; Woods GM
Cell Mol Life Sci; 2020 Jul; 77(13):2507-2525. PubMed ID: 31900624
[TBL] [Abstract][Full Text] [Related]
10. An oral bait vaccination approach for the Tasmanian devil facial tumor diseases.
Flies AS; Flies EJ; Fox S; Gilbert A; Johnson SR; Liu GS; Lyons AB; Patchett AL; Pemberton D; Pye RJ
Expert Rev Vaccines; 2020 Jan; 19(1):1-10. PubMed ID: 31971036
[No Abstract] [Full Text] [Related]
11. Two of a kind: transmissible Schwann cell cancers in the endangered Tasmanian devil (Sarcophilus harrisii).
Patchett AL; Coorens THH; Darby J; Wilson R; McKay MJ; Kamath KS; Rubin A; Wakefield M; Mcintosh L; Mangiola S; Pye RJ; Flies AS; Corcoran LM; Lyons AB; Woods GM; Murchison EP; Papenfuss AT; Tovar C
Cell Mol Life Sci; 2020 May; 77(9):1847-1858. PubMed ID: 31375869
[TBL] [Abstract][Full Text] [Related]
12. Comparative Cytogenetic Mapping and Telomere Analysis Provide Evolutionary Predictions for Devil Facial Tumour 2.
Ingles ED; Deakin JE
Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32354058
[TBL] [Abstract][Full Text] [Related]
13. Tasman-PCR: a genetic diagnostic assay for Tasmanian devil facial tumour diseases.
Kwon YM; Stammnitz MR; Wang J; Swift K; Knowles GW; Pye RJ; Kreiss A; Peck S; Fox S; Pemberton D; Jones ME; Hamede R; Murchison EP
R Soc Open Sci; 2018 Oct; 5(10):180870. PubMed ID: 30473836
[TBL] [Abstract][Full Text] [Related]
14. Heat shock proteins expressed in the marsupial Tasmanian devil are potential antigenic candidates in a vaccine against devil facial tumour disease.
Tovar C; Patchett AL; Kim V; Wilson R; Darby J; Lyons AB; Woods GM
PLoS One; 2018; 13(4):e0196469. PubMed ID: 29702669
[TBL] [Abstract][Full Text] [Related]
15. The differentiation state of the Schwann cell progenitor drives phenotypic variation between two contagious cancers.
Owen RS; Ramarathinam SH; Bailey A; Gastaldello A; Hussey K; Skipp PJ; Purcell AW; Siddle HV
PLoS Pathog; 2021 Nov; 17(11):e1010033. PubMed ID: 34780568
[TBL] [Abstract][Full Text] [Related]
16. A second transmissible cancer in Tasmanian devils.
Pye RJ; Pemberton D; Tovar C; Tubio JM; Dun KA; Fox S; Darby J; Hayes D; Knowles GW; Kreiss A; Siddle HV; Swift K; Lyons AB; Murchison EP; Woods GM
Proc Natl Acad Sci U S A; 2016 Jan; 113(2):374-9. PubMed ID: 26711993
[TBL] [Abstract][Full Text] [Related]
17. Automated Analysis of PD1 and PDL1 Expression in Lymph Nodes and the Microenvironment of Transmissible Tumors in Tasmanian Devils.
Russell GG; Palmieri C; Darby J; Morris GP; Fountain-Jones NM; Pye RJ; Flies AS
Immunol Invest; 2023 Nov; 52(6):661-680. PubMed ID: 37267050
[TBL] [Abstract][Full Text] [Related]
18. The evolution of two transmissible cancers in Tasmanian devils.
Stammnitz MR; Gori K; Kwon YM; Harry E; Martin FJ; Billis K; Cheng Y; Baez-Ortega A; Chow W; Comte S; Eggertsson H; Fox S; Hamede R; Jones M; Lazenby B; Peck S; Pye R; Quail MA; Swift K; Wang J; Wood J; Howe K; Stratton MR; Ning Z; Murchison EP
Science; 2023 Apr; 380(6642):283-293. PubMed ID: 37079675
[TBL] [Abstract][Full Text] [Related]
19. Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils.
Tovar C; Pye RJ; Kreiss A; Cheng Y; Brown GK; Darby J; Malley RC; Siddle HV; Skjødt K; Kaufman J; Silva A; Baz Morelli A; Papenfuss AT; Corcoran LM; Murphy JM; Pearse MJ; Belov K; Lyons AB; Woods GM
Sci Rep; 2017 Mar; 7():43827. PubMed ID: 28276463
[TBL] [Abstract][Full Text] [Related]
20. In vitro competition between two transmissible cancers and potential implications for their host, the Tasmanian devil.
Gérard AL; Owen RS; Dujon AM; Roche B; Hamede R; Thomas F; Ujvari B; Siddle HV
Evol Appl; 2024 Mar; 17(3):e13670. PubMed ID: 38468711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
